> top > docs > PubMed:27693549 > annotations

PubMed:27693549 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-139 Sentence denotes Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
T2 140-281 Sentence denotes Neuroinflammation involves the activation of glial cells, which is associated to the progression of neurodegeneration in Parkinson's disease.
T3 282-551 Sentence denotes Recently, we and other researchers demonstrated that dopamine receptor D3 (D3R)-deficient mice are completely refractory to neuroinflammation and consequent neurodegeneration associated to the acute intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
T4 552-760 Sentence denotes In this study we examined the therapeutic potential and underlying mechanism of a D3R-selective antagonist, PG01037, in mice intoxicated with a chronic regime of administration of MPTP and probenecid (MPTPp).
T5 761-950 Sentence denotes Biodistribution analysis indicated that intraperitoneally administered PG01037 crosses the blood-brain barrier and reaches the highest concentration in the brain 40 min after the injection.
T6 951-1045 Sentence denotes Furthermore, the drug was preferentially distributed to the brain in comparison to the plasma.
T7 1046-1429 Sentence denotes Treatment of MPTPp-intoxicated mice with PG01037 (30 mg/kg, administrated twice a week for five weeks) attenuated the loss of dopaminergic neurons in the substantia nigra pars compacta, as evaluated by stereological analysis, and the loss of striatal dopaminergic terminals, as determined by densitometric analyses of tyrosine hydroxylase and dopamine transporter immunoreactivities.
T8 1430-1533 Sentence denotes Accordingly, the treatment resulted in significant improvement of motor performance of injured animals.
T9 1534-1715 Sentence denotes Interestingly, the therapeutic dose of PG01037 exacerbated astrogliosis and resulted in increased ramification density of microglial cells in the striatum of MPTPp-intoxicated mice.
T10 1716-1859 Sentence denotes Further analyses suggested that D3R expressed in astrocytes favours a beneficial astrogliosis with anti-inflammatory consequences on microglia.
T11 1860-2119 Sentence denotes Our findings indicate that D3R-antagonism exerts a therapeutic effect in parkinsonian animals by reducing the loss of dopaminergic neurons in the nigrostriatal pathway, alleviating motor impairments and modifying the pro-inflammatory phenotype of glial cells.
T1 0-139 Sentence denotes Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
T2 140-281 Sentence denotes Neuroinflammation involves the activation of glial cells, which is associated to the progression of neurodegeneration in Parkinson's disease.
T3 282-551 Sentence denotes Recently, we and other researchers demonstrated that dopamine receptor D3 (D3R)-deficient mice are completely refractory to neuroinflammation and consequent neurodegeneration associated to the acute intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
T4 552-760 Sentence denotes In this study we examined the therapeutic potential and underlying mechanism of a D3R-selective antagonist, PG01037, in mice intoxicated with a chronic regime of administration of MPTP and probenecid (MPTPp).
T5 761-950 Sentence denotes Biodistribution analysis indicated that intraperitoneally administered PG01037 crosses the blood-brain barrier and reaches the highest concentration in the brain 40 min after the injection.
T6 951-1045 Sentence denotes Furthermore, the drug was preferentially distributed to the brain in comparison to the plasma.
T7 1046-1429 Sentence denotes Treatment of MPTPp-intoxicated mice with PG01037 (30 mg/kg, administrated twice a week for five weeks) attenuated the loss of dopaminergic neurons in the substantia nigra pars compacta, as evaluated by stereological analysis, and the loss of striatal dopaminergic terminals, as determined by densitometric analyses of tyrosine hydroxylase and dopamine transporter immunoreactivities.
T8 1430-1533 Sentence denotes Accordingly, the treatment resulted in significant improvement of motor performance of injured animals.
T9 1534-1715 Sentence denotes Interestingly, the therapeutic dose of PG01037 exacerbated astrogliosis and resulted in increased ramification density of microglial cells in the striatum of MPTPp-intoxicated mice.
T10 1716-1859 Sentence denotes Further analyses suggested that D3R expressed in astrocytes favours a beneficial astrogliosis with anti-inflammatory consequences on microglia.
T11 1860-2119 Sentence denotes Our findings indicate that D3R-antagonism exerts a therapeutic effect in parkinsonian animals by reducing the loss of dopaminergic neurons in the nigrostriatal pathway, alleviating motor impairments and modifying the pro-inflammatory phenotype of glial cells.

parkinson

Id Subject Object Predicate Lexical cue
T37 1222-1230 http://purl.obolibrary.org/obo/NCBITaxon_581810 denotes compacta
T38 1262-1270 http://edamontology.org/operation_2945 denotes analysis
T39 1262-1270 http://togodb.biosciencedbc.jp/ontology/kaiko_cdna_interpro%23analysis denotes analysis
T40 1310-1319 http://purl.obolibrary.org/obo/CHEBI_9454 denotes terminals
T41 1310-1319 http://purl.obolibrary.org/obo/CHEBI_9455 denotes terminals
T42 1364-1372 http://purl.obolibrary.org/obo/CHEBI_18186 denotes tyrosine
T43 1389-1397 http://purl.obolibrary.org/obo/CHEBI_18243 denotes dopamine
T44 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_pathological_image%23dose denotes dose
T45 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_organ_weight%23dose denotes dose
T46 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_hematology%23dose denotes dose
T47 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_cell_viability%23dose denotes dose
T48 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_cel_file_attribute%23dose denotes dose
T49 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_biochemistry%23dose denotes dose
T50 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_attribute%23dose denotes dose
T51 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_individual%23dose denotes dose
T52 1565-1569 http://togodb.biosciencedbc.jp/ontology/open_tggates_cell%23dose denotes dose
T53 1752-1761 http://togodb.biosciencedbc.jp/ontology/rpd_spot%23expression denotes expressed
T54 1815-1832 http://purl.obolibrary.org/obo/CHEBI_67079 denotes anti-inflammatory
T55 1815-1832 http://purl.obolibrary.org/obo/CHEBI_35472 denotes anti-inflammatory
T56 1849-1858 http://purl.obolibrary.org/obo/NCBITaxon_493316 denotes microglia
T57 1873-1881 http://purl.obolibrary.org/obo/CHEBI_47867 denotes indicate
T58 1923-1929 http://togodb.biosciencedbc.jp/ontology/knapsack_jamu_herb%23effect denotes effect
T59 1933-1945 http://purl.obolibrary.org/obo/NCBITaxon_58885 denotes parkinsonian
T60 2020-2027 http://togodb.biosciencedbc.jp/ontology/knapsack_bicycle_main%23pathway denotes pathway
T61 2020-2027 http://togodb.biosciencedbc.jp/ontology/dynamic_macrophage_pathway_csml_db%23pathway denotes pathway
T62 2020-2027 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23pathway denotes pathway
T63 2020-2027 http://togodb.biosciencedbc.jp/ontology/knapsack_motorcycle_reaction%23pathway denotes pathway
T64 2020-2027 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23pathway_in_html denotes pathway
T65 2020-2027 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_drug_en%23pathway_in_html denotes pathway
T66 2020-2027 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_drug_en%23pathway denotes pathway
T1 0-13 http://edamontology.org/topic_0202 denotes Pharmacologic
T2 28-36 http://purl.obolibrary.org/obo/CHEBI_18243 denotes dopamine
T3 110-115 http://togodb.biosciencedbc.jp/ontology/sahg_complex%23model denotes model
T4 119-128 http://purl.obolibrary.org/obo/NCBITaxon_58885 denotes Parkinson
T5 131-138 http://togodb.biosciencedbc.jp/ontology/hgold_main%23disease denotes disease
T6 131-138 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease%23entry denotes disease
T7 131-138 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23entry denotes disease
T8 261-270 http://purl.obolibrary.org/obo/NCBITaxon_58885 denotes Parkinson
T9 273-280 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23entry denotes disease
T10 273-280 http://togodb.biosciencedbc.jp/ontology/hgold_main%23disease denotes disease
T11 273-280 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease%23entry denotes disease
T12 299-304 http://togodb.biosciencedbc.jp/ontology/kaiko_cdna_cluster%23other denotes other
T13 299-304 http://togodb.biosciencedbc.jp/ontology/riken_ssbc_crystallization_kit%23other denotes other
T14 317-329 http://edamontology.org/operation_2246 denotes demonstrated
T15 335-343 http://purl.obolibrary.org/obo/CHEBI_18243 denotes dopamine
T16 501-507 http://purl.obolibrary.org/obo/CHEBI_29309 denotes methyl
T17 525-543 http://purl.obolibrary.org/obo/CHEBI_78712 denotes tetrahydropyridine
T18 525-543 http://purl.obolibrary.org/obo/CHEBI_26921 denotes tetrahydropyridine
T19 619-628 http://purl.obolibrary.org/obo/NCBITaxon_127244 denotes mechanism
T20 648-658 http://purl.obolibrary.org/obo/CHEBI_48705 denotes antagonist
T21 648-658 http://purl.obolibrary.org/obo/CHEBI_67199 denotes antagonist
T22 648-658 http://purl.obolibrary.org/obo/CHEBI_48706 denotes antagonist
T23 741-751 http://purl.obolibrary.org/obo/CHEBI_8426 denotes probenecid
T24 777-785 http://edamontology.org/operation_2945 denotes analysis
T25 777-785 http://togodb.biosciencedbc.jp/ontology/kaiko_cdna_interpro%23analysis denotes analysis
T26 786-795 http://purl.obolibrary.org/obo/CHEBI_47867 denotes indicated
T27 896-909 http://edamontology.org/data_2140 denotes concentration
T28 968-972 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23drug_in_html denotes drug
T29 968-972 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_drug%23entry denotes drug
T30 968-972 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_disease_en%23drug denotes drug
T31 968-972 http://purl.obolibrary.org/obo/CHEBI_23888 denotes drug
T32 968-972 http://togodb.biosciencedbc.jp/ontology/kegg_medicus_drug_en%23entry denotes drug
T33 1020-1030 http://edamontology.org/operation_2424 denotes comparison
T34 1099-1101 http://togodb.biosciencedbc.jp/ontology/kaiko_cdna_cluster%23mg denotes mg
T35 1217-1221 http://purl.obolibrary.org/obo/NCBITaxon_560929 denotes pars
T36 1217-1230 http://purl.obolibrary.org/obo/NCBITaxon_509376 denotes pars compacta

Parkinson

Id Subject Object Predicate Lexical cue
T1 852-857 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T2 852-871 http://purl.obolibrary.org/obo/UBERON_0000120 denotes blood-brain barrier
T3 858-863 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T4 917-922 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T5 1011-1016 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T6 1200-1216 http://purl.obolibrary.org/obo/UBERON_0002038 denotes substantia nigra
T7 1200-1230 http://purl.obolibrary.org/obo/UBERON_0001965 denotes substantia nigra pars compacta
T8 1680-1688 http://purl.obolibrary.org/obo/UBERON_0002435 denotes striatum